Hydroxyurea Adherence for """"""""Personal Best"""""""" in Sickle Cell Treatment: """"""""HABIT"""""""" The overall goal is to test an intervention to improve the health of children with sickle cell disease (SCD) by enhancing long-term self-managed adherence to hydroxyurea (HU) therapy. Sickle cell disease (SCD), an inherited blood disorder affecting under-served populations in the U.S., is characterized by anemia, painful crises, reduced quality of life (QOL) and high health care utilization. HU is an oral, once-daily medication and sole approved drug for SCD therapy. HU dramatically reduces symptoms, morbidity and mortality, improves quality of life (QOL) and induces increased fetal hemoglobin (HbF) level. HbF has a stable dose- dependent relationship to HU, making it an excellent biomarker to monitor medication adherence. As no uniform HbF target exists, individualized HU-induced HbF levels should reach a stable """"""""personal best"""""""" response to treatment, but often do not. Many youth do not fully benefit from HU due to inadequate integration of daily adherence into their routine self-managed habit. Barriers to adherence may include incomplete knowledge of drug benefit and cultural, logistical and developmental impediments. Challenges specific to HU include limited awareness about benefits and concerns about its safety. Youth also need a developmentally appropriate transition of self-management from their parents. Community-based health workers (CHW) are a well-established partner of the medical home to address barriers through culturally, behaviorally and developmentally aligned intervention. We hypothesize that a unique combination of two established interventions, community-based support for chronic pediatric illness and mobile health communication, will improve self-managed adherence to HU.
The specific aims of this 6 month randomized controlled trial are to: 1) Assess the feasibility and acceptability by parents, youth and CHWs of a 6 month intervention of CHW support, augmented by tailored text messages, to improve adherence to HU therapy;2) Estimate the effect size of the intervention on HU adherence (primary outcome);and on 3) Cooperative youth-parent self-management responsibility, QOL and resource use (secondary outcomes) at 6 months. The goal of this feasibility study is to support the design of a multi-site randomized tria to improve HU adherence through enhanced disease self-management in children with SCD. This research may also inform interventions for other pediatric chronic illnesses in underserved communities.
To improve hydroxyurea medication adherence in a group of youth/parent dyads with sickle cell disease on a variety of health and self-management outcomes, this randomized controlled feasibility trial, Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT, will test the feasibility of an intervention with community health worker intervention, augmented by tailored text messaging. Results from this study will inform design of a larger multi-site trial to test the effectiveness of the intervetion.
|Hsu, Lewis L; Green, Nancy S; Donnell Ivy, E et al. (2016) Community Health Workers as Support for Sickle Cell Care. Am J Prev Med 51:S87-98|
|Smaldone, Arlene; Findley, Sally; Bakken, Suzanne et al. (2016) Study protocol for a randomized controlled trial to assess the feasibility of an open label intervention to improve hydroxyurea adherence in youth with sickle cell disease. Contemp Clin Trials 49:134-42|
|Green, Nancy S; Manwani, Deepa; Qureshi, Mahvish et al. (2016) Decreased fetal hemoglobin over time among youth with sickle cell disease on hydroxyurea is associated with higher urgent hospital use. Pediatr Blood Cancer 63:2146-2153|
|Smaldone, Arlene; Stockwell, Melissa S; Osborne, Jennel C et al. (2015) Adolescent and parent use of new technologies for health communication: a study in an urban latino community. J Public Health Res 4:376|
|Bekele, ElShadey; Thornburg, Courtney D; Brandow, Amanda M et al. (2014) Do difficulties in swallowing medication impede the use of hydroxyurea in children? Pediatr Blood Cancer 61:1536-9|